arrow
M

Martin Metzenmacher

west german cancer centre
H指数:14
被引数:844

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event

肺癌一线/诱导治疗中的亚临床肺栓塞 - 一个持续存在的临床相关不良事件

2026-09-220
OAAI
Ten-year Overall Survival in Resectable Stage-III NSCLC - Results of the Randomized ESPATUE Trial – Long-term Survival and Competing Risk Analysis
2026-02-040
PRE
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer

病理完全缓解预测III期非小细胞肺癌新辅助诱导化疗及放化疗后的长期生存率

2025-11-190
OAAI
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer

[18F]FDG-PET/CT在评估Ⅱ期-Ⅲ期小细胞肺癌诱导化疗及同期放化疗期间肿瘤反应动力学中的应用

2025-11-170
OAAI
Early Years, Advanced Disease: The Unmet Need in Young Adults with Non-Small Cell Lung Cancer

早年,晚期疾病:非小细胞肺癌年轻成年患者中的未满足需求

2025-09-240
OAAI
BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOK

Bcl-b通过直接抑制BOK促进肺癌侵袭

CELLS
IF5.2
2025-02-090
OAAI
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNA

通过循环无细胞RNA微创确定胰腺导管腺癌 (PDAC) 亚型

2024-10-310
OA
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome

寡转移非小细胞肺癌: 局部和当代系统治疗方法对临床结果的影响

2024-09-254
OAAI
Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE)
2024-08-281
OAAI
Comprehensive pan-cancer analysis of cfDNA methylation marks in tumors reveals complex epigenetic regulatory circuits and diagnostic biomarkers
2024-03-220
PRE
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies

未知原发癌的综合生物标志物诊断,以确定符合精确医疗治疗条件的患者

2024-03-012
OA
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with
2024-01-010
OAAI
68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study

68Ga-SSO-120 PET用于小细胞肺癌患者初始分期的单中心回顾性研究

2023-07-205
OA
SUVmax Above 20 in 18F-FDG PET/CT at Initial Diagnostic Workup Associates with Favorable Survival in Patients with Cancer of Unknown Primary

在初次诊断检查时,18F-FDG PET/CT中SUVmax高于20与未知原发癌患者的良好生存率相关

2023-06-155
OA